🧩 Is a Hidden Novartis Acquisition Playing Out Through Recordati & Amarin?
I’m genuinely surprised no one has pieced this together.
The Recordati deal isn’t just a licensing deal or an EU restructuring story. It’s a full sequence transition that mirrors a 2019 Novartis playbook used to shift endocrine assets to Recordati before exiting the space.
Now that same structure surrounds Vazkepa.
Seven detailed posts walk through the pattern: strategic precedent, leadership migration, FDA approvals under Recordati, and structural design that locks out competitors and streamlines M&A execution.
What we’re seeing is not coincidental. This structure lowers execution risk and narrows optionality.
When you follow the path from Novartis to Recordati to Amarin, the acquirer doesn’t need to declare itself. The structure does it for them.
Recordati has a long and proven track record of functioning as a commercialization bridge for Novartis, acting as a downstream proxy to maintain operational continuity while upstream ownership is restructured. The Amarin handoff follows that same pattern.
🔹 The Recordati agreement resembles a gated carveout, a structural prerequisite for acquisition 🔹 Amarin’s EU business was cleared off the books, leaving high margin royalties and lean ops 🔹 Barclays was retained, Sarissa streamlined the company, and redacted terms likely contain change of control clauses
Once key milestones fall — France or Germany reimbursement, China NRDL, or IP validation on LR-ETEPA — the stock rerates.
At that point the acquisition becomes a formality.
Sarissa has worked with Novartis before. That history isn’t random. It’s consistent with this entire setup. Novartis was likely given the block, positioned to win without a competitive auction.
Market Data 
Markets 
